IP Library Granted Patent US 10,653,653
Granted Patent B2
US 10,653,653 · App. 16/071,485 · Granted May 19, 2020

Salts of 5-aminolevulinic acid and derivatives

Inventors: Ming Zhao (Darien, IL); Li-Ming Zhou (Darien, IL)
A61K31/197A61K9/006A61K9/0009A61K9/0014A61K9/06A61K9/08A61K41/0061A61K45/06A61K47/12A61P17/06A61P17/10A61P35/00C07C53/16C07C229/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,653
App. No.
16/071,485
Granted
May 19, 2020
Kind
B2
Abstract

The present disclosure provides new salts of 5-aminolevulinic acid (5-ALA) and new salts of 5-ALA esters, their preparation, formulation and use as photosensitizing agents in photodynamic therapy, diagnosis and cosmetic cares.

Claims (15)

1. A salt having formula (I):

H 2 NCH 2 COCH 2 CH 2 COOR.Cl 3 C—COOH  (I)

wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, sec-propyl, sec-butyl, tert-butyl, sec-pentyl, sec-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, 2-methylbenzyl, 4-methylbenzyl, 4-chloro-benzyl, 2-nitro-benzyl, 4-nitro-benzyl, 2-isopropylbenzyl, 4-isopropylbenzyl, and 4-fluoro-benzyl.

2. The salt of claim 1 , wherein R is selected from the group consisting of hydrogen, methyl.

3. A salt of claim 1 selected from the group consisting of 5-aminolevulinic acid 2,2,2-trichloroacetate, methyl 5-aminolevulinate 2,2,2-trichloroacetate, hexyl 5-aminolevulinate 2,2,2-trichloroacetate, benzyl 5-aminolevulinate 2,2,2-trichloroacetate, and 4-methylbenzyl 5-aminolevulinate 2,2,2-trichloroacetate.

4. A pharmaceutical composition comprising the salt of claim 1 and at least one pharmaceutically or cosmetically acceptable carrier or an excipient.

5. A salt of claim 1 , wherein the salt is 5-aminolevulinic acid 2,2,2-trichloroacetate.

6. A salt of claim 1 , wherein the salt is methyl 5-aminolevulinate 2,2,2-trichloroacetate.

7. A salt of claim 1 , wherein the salt is hexyl 5-aminolevulinate 2,2,2-trichloroacetate.

8. A salt of claim 1 , wherein the salt is benzyl 5-aminolevulinate 2,2,2-trichloroacetate.

9. A salt of claim 1 , wherein the salt is 4-methylbenzyl 5-aminolevulinate 2,2,2-trichloroacetate.

10. The pharmaceutical composition of claim 4 , wherein the salt is selected from the group consisting of 5-aminolevulinic acid 2,2,2-trichloroacetate, methyl 5-aminolevulinate 2,2,2-trichloroacetate, hexyl 5-aminolevulinate 2,2,2-trichloroacetate, benzyl 5-aminolevulinate 2,2,2-trichloroacetate, and 4-methylbenzyl 5-aminolevulinate 2,2,2-trichloroacetate.

11. The pharmaceutical composition of claim 4 , wherein the salt is 5-aminolevulinic acid 2,2,2-trichloroacetate.

12. The pharmaceutical composition of claim 4 , wherein the salt is methyl 5-aminolevulinate 2,2,2-trichloroacetate.

13. The pharmaceutical composition of claim 4 , wherein the salt is hexyl 5-aminolevulinate 2,2,2-trichloroacetate.

Priority Claims (1)
CN 2016 1 0568868 · Jul 20, 2016 · national
Continuity (2)
Provisional Application 62286977 · Jan 26, 2016
Related Publication 20190022044A1 · Jan 24, 2019
Cited By (2)
US 12,427,345 US 12,623,094